www.fdanews.com/articles/81773-solvay-s-tricor-q3-u-s-sales-up-8-1-pct
SOLVAY'S TRICOR Q3 U.S. SALES UP 8.1 PCT
October 19, 2005
U.S. sales for Solvay's (SOLBt.BR: Quote, Profile, Research) lipid disorder treatment Tricor rose 8.1 percent in the third quarter to $225 million (188.4 million euros), according to figures released by Abbot Laboratories (ABT.N: Quote, Profile, Research).
Abbott, which markets the drug in the United States for the Belgian drug and chemical company, published the figures in its earnings report on Wednesday.